Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.33 |
| ▸ | MGMT | P16455 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11222090 | 0.81 | PDPK1 (0.32) | — | |
| SCHEMBL6533714 | 0.81 | — | — | |
| SCHEMBL1020378 | 0.80 | CYP1A2 (0.33) | CDK2 | |
| SCHEMBL17060282 | 0.80 | PDPK1 (0.32) | — | |
| SCHEMBL5066802 | 0.78 | ADORA1 (0.37) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL9176115 | 0.78 | GDA (0.32) | — | |
| SCHEMBL9474847 | 0.77 | KDM4E (0.30) | — | |
| SCHEMBL6379581 | 0.77 | HRH2 (0.37) | — | |
| SCHEMBL215053 | 0.75 | ADORA2A (0.40) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8523000 | 0.75 | INSR (0.39) | CDK1CCNB1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 788 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710023-B2 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | claimed |
| US-20140080894-A1 | ENHANCED BIODISTRIBUTION OF OLIGOMERS | GROOVE BIOPHARMA CORPORATION | 2014-03-20 | — | — | US | claimed |
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | claimed |
| WO-2012119051-A2 | ENHANCED BIODISTRIBUTION OF OLIGOMERS | GROOVE BIOPHARMA CORPORATION (US) | 2012-09-07 | — | — | WO | claimed |
| US-20120077866-A1 | ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | claimed |
| US-8093224-B2 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | claimed |
| US-20110117646-A1 | ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | claimed |
| US-7915231-B2 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | claimed |
| US-20090275133-A1 | ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | claimed |
| US-20060024727-A1 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | claimed |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| WO-2024151673-A2 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151685-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-0355135-B1 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1993-08-04 | — | — | EP | disclosed |
| US-4997926-A | Viricides | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1991-03-05 | — | — | US | disclosed |
| EP-0355135-A4 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES. | SCRIPPS CLINIC RES (US) | 1990-04-09 | — | — | EP | disclosed |
| EP-0355135-A1 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1990-02-28 | — | — | EP | disclosed |
| WO-1989004662-A1 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1989-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | CHI3L2, CHI3L1, FGF2 | CDK1 4090/4885CCNB1 3995/4885CCNA2 2553/4885 |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | CDK1 4833/4885CCNB1 4708/4885CCNA2 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.